Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 523

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

Knutson, Sarah K., Kawano, Satoshi, Minoshima, Yukinori, Warholic, Natalie M., Huang, Kuan-Chun, Xiao, Yonghong, Kadowaki, Tadashi, Uesugi, Mai, Kuznetsov, Galina, Kumar, Namita, Wigle, Tim J., Klaus, Christine R., Allain, Christina J., Raimondi, Alejandra, Waters, Nigel J., Smith, Jesse J., Porter-Scott, Margaret, Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A., Richon, Victoria M., Uenaka, Toshimitsu, Pollock, Roy M., Kuntz, Kevin W., Yokoi, Akira, Keilhack, Heike·2014·Molecular Cancer Therapeutics

Abstract

Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL). These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymatic activity in these cancers. We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small molecule inhibitors of EZH2. Although both compounds are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals. Here, we characterize the activity of EPZ-6438 in preclinical models of NHL. EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concentration- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells. Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations. Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues. Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compound treatment in two EZH2-mutant xenograft models. These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers. Mol Cancer Ther; 13(4); 842–54. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-13-0773

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 523

Metadata

Authors
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Waters, N. J., Smith, J. J., Porter-Scott, M., Chesworth, R., Moyer, M. P., Copeland, R. A., Richon, V. M., Uenaka, T., Pollock, R. M., Kuntz, K. W., Yokoi, A., & Keilhack, H.
Venue
Molecular Cancer Therapeutics
Published
2014-04-01
Volume
13
Issue
4
Pages
842-854
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2100630390
Cited by
523
References
7
FWCI
23.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0773
The paper
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Waters, N. J., Smith, J. J., Porter-Scott, M., Chesworth, R., Moyer, M. P., . . . Keilhack, H. (2014). Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.